Full-Time

Senior Clinical Oversight Manager

Kailera Therapeutics

Kailera Therapeutics

51-200 employees

Clinical-stage obesity and metabolic drugs developer

Compensation Overview

$143k - $175k/yr

+ Annual Bonus + Equity Grants + 401(k) Match + Tuition Reimbursement + Commuter Benefits + Wellness Stipend

Waltham, MA, USA

Hybrid

On-site 3-4 days per week; hybrid work arrangement.

Category
Biology & Biotech (2)
,
Requirements
  • Minimum of 8+ years of clinical trial experience with strong knowledge of the clinical development process
  • Experience with Phase I–III clinical trials, risk-based monitoring, and CRA Management
  • Proficient in oversight tools and systems (CTMS, eTMF, dashboards, Microsoft Office)
  • Experience with Vendor oversight, KPI tracking, and issue management
  • Strong leadership, collaboration, and communication skills with the ability to manage and motivate team members (e.g., internal staff and external investigators/consultants)
  • Excellent organizational, analytical, and interpersonal skills; able to work independently and in teams
  • In-depth knowledge of ICH-GCP, FDA, EMA, and global regulatory requirements
  • Ability to manage complexity in a fast-paced environment
  • Must have strong clinical study management, communication (oral and written), and analytical skills
  • Must be able to travel
  • Bachelor’s degree in a scientific or healthcare-related field
Responsibilities
  • Develops the Clinical Monitoring Oversight strategy across studies, including development and oversight of Clinical Monitoring Oversight SOPs and templates, Clinical Oversight Monitoring plans, managing Monitoring Oversight Service Provider (SP) activities, providing study/program/SP level reporting, and leading monthly TMF health checks
  • Evaluates and provides recommendations to the study team on Oversight Service Provider activities to ensure the appropriate scope of work, oversight, and training of clinical oversight CRAs to achieve study milestones within agreed upon timelines, budget and quality
  • Assigns oversight visits at trial sites based on strategic criteria to evaluate compliance of trials with local regulatory requirements; overall data quality and integrity; and human subject protection
  • Provides oversight on service provider execution of clinical trial activities in accordance with Kailera SOPs, ICH Guidelines, and Good Clinical Practice (GCP)
  • Develops key performance indicators (KPIs) and evaluates service provider operational data against KPIs to identify potential performance gaps
  • Collaborates with the Clinical Oversight team, Clinical Quality Management, and Clinical Study Team to implement corrective actions and monitor progress through resolution
  • Facilitate resolution of region specific and site management related challenges
  • Acts on behalf of Business Operations on cross-functional project teams; interacts with internal and external groups
  • Assist with creation and delivery of department initiatives, improvement plans, and/or training
  • Selects and oversees Oversight CRAs globally, driving the team to ensure study deliverables are met with efficiency and quality in accordance with applicable SOPs, regulations, GCP, Key Performance Indicators (KPIs), and study-specific requirements
  • Responsible for ensuring Oversight CRAs maintain their sites/studies as inspection ready, including the TMF, for health authority inspections
  • Conduct periodic quality visits for Oversight CRAs, as needed
  • Ensure the oversight CRAs are reviewing and ensuring data integrity, accuracy, and completeness at the clinical study sites
  • Support and liaise with clinical site personnel, as needed
  • Review contracts and approve vendor invoices

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on obesity and related metabolic conditions, acquiring externally sourced drug candidates to advance multiple assets into clinical development. Its lead program, KAI-9531, is an injectable dual agonist of GLP-1 and GIP receptors for obesity and type 2 diabetes, with a pipeline that also includes an oral GLP-1 receptor agonist (KAI-7535), an oral tablet form of KAI-9531, and an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors (KAI-4729). The company secured exclusive rights to develop four metabolic assets from Jiangsu Hengrui Pharmaceuticals and is backed by a roughly $400 million Series A to accelerate development. Led by CEO Ron Renaud and with a board chaired by John F. Milligan, Kailera aims to bring multiple metabolic therapies toward commercialization to improve patient outcomes.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2024

Simplify Jobs

Simplify's Take

What believers are saying

  • $718.8M IPO in April 2026 funds three global Phase 3 ribupatide trials.
  • Hengrui partnership delivers China Phase 3 data and advances oral ribupatide.
  • No GI discontinuations in Phase 2 supports superior tolerability profile.

What critics are saying

  • Zepbound captures 60% market share, blocks Kailera reimbursement by 2028.
  • Pfizer-Metsera accelerates oral GLP-1 Phase 3, erodes Kailera edge in 2027.
  • KaiNETIC-1/2/3 miss superiority endpoints, fail FDA approval in 2028.

What makes Kailera Therapeutics unique

  • Oral ribupatide achieves 12.1% weight loss at 26 weeks without plateau.
  • Ribupatide shows 17.7% weight loss in Chinese Phase 3 versus 1.4% placebo.
  • Pipeline spans injectable dual, oral, and tri-agonists targeting GLP-1/GIP/glucagon.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kailera Therapeutics who can refer or advise you

Benefits

Health Insurance

Wellness Program

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Tuition Reimbursement

Commuter Benefits

Disability and Life Insurance

Equity Grants

Stock Options

Paid Holidays

Paid Vacation

Paid Sick Leave

Flexible Time Off

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Tuition Reimbursement

Commuter Benefits

Phone/Internet Stipend

Home Office Stipend

Mental Health Support

Family Planning Benefits

Fertility Treatment Support

Tuition Reimbursement

Company News

Kailera Therapeutics
Apr 18th, 2026
Kailera Therapeutics Announces Pricing of Initial Public Offering | Thu, 04/16/2026 - 19:25

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common

Hoodline
Mar 30th, 2026
Waltham obesity-drug upstart races toward IPO after near-billion cash haul.

Waltham obesity-drug upstart races toward IPO after near-billion cash haul. Published on March 30, 2026 Kailera Therapeutics, the Waltham biotech working on next-generation obesity medicines, filed paperwork on March 30, 2026 to go public after pulling in nearly $1 billion in private capital. Operating from a growing Waltham campus, the company has scaled to roughly 145 employees while pushing forward a pipeline of injectable and oral GLP-1 and multi-agonist drug candidates. The IPO move caps a rapid rise for a venture-backed outfit that now wants public-market cash to fuel global late-stage trials. According to the Boston Business Journal, Kailera has formally submitted documents signaling plans for an initial public offering. The outlet reports the company has attracted close to $1 billion in private funding and employs about 145 people in the Boston suburbs. Near-Billion war chest fuels IPO ambitions. Kailera emerged from stealth with a $400 million launch financing and later added a $600 million Series B, giving it roughly $1 billion in commitments earmarked for late-stage development. Industry reporting indicates Bain Capital and other major investors led that follow-on round and that the capital is intended to support global Phase 3 programs and broader development efforts, according to FierceBiotech. Late-Stage data and A pill on deck. Kailera's lead program focuses on ribupatide (KAI-9531), including a once-daily oral version that the companies say delivered mean weight loss of up to 12.1% at 26 weeks in a Phase 2 obesity trial in China. A press release from Kailera Therapeutics notes that Hengrui plans to move the oral candidate into Phase 3 in China while Kailera pursues global studies. The executive roster lists Ron Renaud as the company's president and chief executive officer, per Kailera Therapeutics. Next steps and what it means for Waltham. The IPO filing starts the Securities and Exchange Commission review and investor outreach that typically precede a public offering, with timing and pricing still dependent on market conditions. If completed, the deal proceeds would likely go toward funding global Phase 3 trials and expanding Kailera's research operations in Waltham, with the potential for additional local hiring and lab buildout. The IPO window has been more receptive this year to well-capitalized, late-stage biotechs, which could make a 2026 public debut more attainable for Kailera, according to FierceBiotech.

MENA Fintech Association
Dec 1st, 2025
Kailera Therapeutics files for US IPO to fund obesity drugs.

Kailera Therapeutics files for US IPO to fund obesity drugs. Powered by Kailera Therapeutics files for US IPO to advance obesity drug pipeline. SAN DIEGO, United States - March 27, 2026 - Kailera Therapeutics Inc. filed confidentially for a US initial public offering to fund development of its obesity drug candidates. The company targets a Nasdaq listing under ticker KLRA, with proceeds supporting late-stage trials of lead asset ribupatide. The move capitalizes on surging investor interest in GLP-1 therapies amid a global obesity treatment boom. Overview. Kailera, a clinical-stage biotechnology company incorporated in May 2024, submitted its S-1 registration statement to the SEC without disclosing share count, price range, or anticipated proceeds. Net proceeds will fund ribupatide (KAI-9531, a Phase 3 injectable GLP-1/GIP dual agonist), oral ribupatide (Phase 2 planned), KAI-7535 (oral GLP-1, US Phase 2 planned), and KAI-4729 (a Phase 1 tri-agonist). J.P. Morgan and Jefferies serve as underwriters. The company reported a $149 million net loss in 2025 and $368.7 million accumulated deficit, with $546 million cash as of December 2025. Announcement specifics. Kailera, a clinical-stage biotechnology company incorporated in May 2024, submitted its S-1 registration statement to the SEC without disclosing share count, price range, or anticipated proceeds. Net proceeds will fund ribupatide (KAI-9531, a Phase 3 injectable GLP-1/GIP dual agonist), oral ribupatide (Phase 2 planned), KAI-7535 (oral GLP-1, US Phase 2 planned), and KAI-4729 (a Phase 1 tri-agonist). J.P. Morgan and Jefferies serve as underwriters. The company reported a $149 million net loss in 2025 and $368.7 million accumulated deficit, with $546 million cash as of December 2025. Executive commentary. "With an increasing global population affected by obesity and limited options for those living with higher BMIs, the need for effective treatment options has never been greater." - Ron Renaud, CEO at Kailera Therapeutics Why it matters: This statement underscores Kailera's strategy to compete with market leaders like Eli Lilly's Zepbound by targeting underserved patient populations, with clinical data showing ribupatide achieving up to 23.6% weight loss. Industry context. The obesity treatment market has exploded, dominated by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide. Kailera in-licensed its pipeline from China's Hengrui Pharma and raised $400 million in Series A funding in 2024, followed by a $600 million Series B round in 2025 led by Bain Capital and Atlas Venture, with participation from Qatar Investment Authority (QIA). QIA's Series B investment signals growing MENA sovereign wealth interest in high-growth biotechnology, potentially catalyzing additional regional capital deployment into global health innovation. Kailera's diversified pipeline - spanning injectable and oral formulations - addresses adherence challenges and efficacy gaps for higher-BMI patients in a market projected to exceed $100 billion. Outlook. The IPO positions Kailera to accelerate Phase 3 clinical readouts expected in 2027-2028, intensifying competition in the obesity therapeutics sector. Success depends on trial data differentiation and pricing strategy amid an increasingly crowded competitive landscape. Reach industry leaders, innovators, and decision-makers in the fintech community. Submit Your PR

Dealroom.co
Oct 15th, 2025
Kailera Therapeutics company information, funding & investors

Kailera Therapeutics, a clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions. Here you'll find information about their funding, investors and team.

STAT News
Oct 14th, 2025
Kailera Therapeutics, an obesity drug startup, raises $600 million

Kailera Therapeutics, an obesity drug startup, raises $600 million. The financing round is one of the biggest in biotech this year. Investors announced one of the biggest private financing rounds of the year for a biotech company Tuesday, pouring $600 million into obesity startup Kailera Therapeutics. Bain Capital's private equity group led the financing, which also included Royalty Pharma and sovereign wealth funds in Canada and Qatar. Several of Kailera's founding investors also put more money into the company. The deal underlines the persistent heightened attention being paid to weight loss drugs, even after multiple years of activity and some clinical disappointments. Kailera's Series B round was announced almost exactly one year after the startup launched with $400 million. It also comes shortly after Pfizer announced plans to buy another privately held obesity drug developer, Metsera, for $4.9 billion.